ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

Updated results from an early trial suggest an effective gene therapy for hemophilia A could be within reach.

By Ned Pagliarulo • Dec. 9, 2017

Pfizer's PARP inhibitor showcases efficacy in late-stage trial

For breast cancer patients with specific mutations, treatment with talazoparib resulted in three additional months of progression-free survival versus chemo. 

By Jacob Bell • Dec. 8, 2017

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Prescribed Reading: Dealmaking begins to pick up as 2018 approaches

It's been a slow year for deals, but it looks like Gilead's buy of Kite could be a catalyst for more M&A. 

By Lisa LaMotta • Dec. 8, 2017

Arrowhead data hits the target in chronic hep B

New data from the Arrowhead ARC-520 Phase 2 trial in chronic hepatitis B points to a sustained host response.

By Suzanne Elvidge • Dec. 8, 2017

Sage stock soars with positive Phase 2 in major depression

Hope increases for patients with major depressive disorder as Sage Therapeutics' SAGE-217 meets its primary endpoint, with rapid and durable effects over six weeks of treatment.

By Suzanne Elvidge • Dec. 8, 2017

Chasing leaders, Juno rides CAR-T momentum into ASH

This year's ASH conference will be an important milestone in Juno's comeback bid, showcasing early progress of its lead CAR-T therapy in lymphoma. 

By Ned Pagliarulo • Dec. 7, 2017

Roche's Tecentriq combo cuts risk of lung cancer progression

Detailed results from the Swiss pharma's IMpower150 study boost Tecentriq's profile in the frontline lung cancer setting.

By Ned Pagliarulo • Dec. 7, 2017

Madrigal NASH data sounds a sweet note, stock soars

The market is playing the biotech's tune, as positive NASH data pleases shareholders.

By Suzanne Elvidge • Dec. 7, 2017

FDA cautiously lifts holds on combo studies of checkpoint inhibitors

Concerns of a potential class-wide safety risk had prompted the agency to shut down several studies pairing PD-1/L1 blockers with immunomodulatory drugs in multiple myeloma.

By Ned Pagliarulo • Dec. 6, 2017

Galectin drops 40% on negative NASH result

The biotech's stock took a major hit when its NASH drug didn't work in the overall study population.

By Lisa LaMotta • Dec. 5, 2017

J&J, Sanofi ranked best for clinical trial transparency

Both companies had 100% transparency rates related to new drugs they received approval for in 2014, according to a new study from Bioethics International.

By Jacob Bell • Dec. 5, 2017

Ra shares tank on Soliris comparison

Despite positive data for RA101495, the markets haven't seemed impressed, and stock value has dropped by over 37% at close.

By Suzanne Elvidge • Dec. 5, 2017

Ironwood pushing through mid-stage trials with nephropathy drug

Safety and PK studies showed early signs of benefits for Ironwood's lead pipeline candidate.

By Suzanne Elvidge • Dec. 5, 2017

Updated: Sanofi discontinues C. diff candidate in blow to vaccine unit

Disclosure of the setback came on the heels of a damaging admission by Sanofi that its dengue vaccine could intensify subsequent infections in certain patients. 

By Ned Pagliarulo • Dec. 4, 2017

7 Biopharmas to watch at ASH 2017

This year's ASH meeting looks to be a key milestone for several closely watched cell and gene therapy companies. 

By Ned Pagliarulo • Dec. 4, 2017

Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC

Imfinzi's miss in non-small cell lung cancer was a huge setback for the British pharma and could relegate the drug as a never-was in the checkpoint inhibitor race.

By Lisa LaMotta • Dec. 4, 2017

Biotech of the Year: Vertex Pharmaceuticals

Vertex watched its stock more than double in 2017 as the company cornered the multi-billion-dollar cystic fibrosis market with strong products and a promising pipeline.

By Jacob Bell • Dec. 4, 2017

Disruption of the Year: Long-Acting Hemophilia Drugs

Longer-acting treatments and gene therapies are likely to steal away hundreds of millions of dollars worth of revenue from established products in the coming years.

By Jacob Bell • Dec. 4, 2017

The BioPharma Dive Awards for 2017

The 2017 BioPharma Dive Awards recognize the industry’s top innovators and disruptors. These executives, companies and trends are transforming the industry and shaping what's to come.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 4, 2017

Bayer unblinds cancer drug study early to investigate patient deaths

A data monitoring committee raised the alarm after finding more fractures and deaths occurred among patients treated with Xofigo and two other drugs than those on placebo.   

By Ned Pagliarulo • Dec. 1, 2017

Prescribed Reading: Industry CEOs talk PRVs, IPR, PCSK9

Leschly suggests PRVs should be an alternative source of revenue for biotechs; ear health R&D is all clogged up; and execs agree the IPR process should be thrown out. 

By Lisa LaMotta • Dec. 1, 2017

RespireRx breathes easy with PACE data

The company's Phase 2b results are a breath of fresh air for sleep apnea patients.

By Suzanne Elvidge • Dec. 1, 2017

Auris dumps Phase 3 trial after failure

The Swiss biotech terminated the late-stage trial following a setback in the HEALOS study of its hearing loss drug candidate. 

By Lisa LaMotta • Nov. 28, 2017

Pfizer, Merck KGaA's Bavencio falls short in gastric cancer study

The two companies were fourth to market with Bavencio, making it more challenging to differentiate the PD-L1 blocker from rival therapies.

By Ned Pagliarulo • Nov. 28, 2017

Regeneron scraps another Eylea combo

Results from two mid-stage studies indicate Eylea plus nesvacumab didn't beat out the blockbuster drug by itself, pushing Regeneron to ditch Phase 3 development.

By Jacob Bell • Nov. 27, 2017